NICOLA HANANIA to Forced Expiratory Volume
This is a "connection" page, showing publications NICOLA HANANIA has written about Forced Expiratory Volume.
Connection Strength
4.433
-
Examining the Effects of Age on Health Outcomes of Chronic Obstructive Pulmonary Disease: Results From the Genetic Epidemiology of Chronic Obstructive Pulmonary Disease Study and Evaluation of Chronic Obstructive Pulmonary Disease Longitudinally to Identify Predictive Surrogate Endpoints Cohorts. J Am Med Dir Assoc. 2017 Dec 01; 18(12):1063-1068.
Score: 0.556
-
The bronchodilator response to salmeterol is maintained with regular, long-term use in patients with COPD. Pulm Pharmacol Ther. 2005; 18(1):19-22.
Score: 0.227
-
Sex differences and determinants of anxiety symptoms in patients with COPD initiating pulmonary rehabilitation. Respir Med. 2024 06; 227:107633.
Score: 0.216
-
Predictors of premature discontinuation and prevalence of dropouts from a pulmonary rehabilitation program in patients with chronic obstructive pulmonary disease. Respir Med. 2022 03; 193:106742.
Score: 0.185
-
Omalizumab in Asthma with Fixed Airway Obstruction: Post Hoc Analysis of EXTRA. J Allergy Clin Immunol Pract. 2022 01; 10(1):222-228.
Score: 0.180
-
Improvement in Lung Function and Patient-Reported Outcomes in Patients with COPD with Comorbid Anxiety and Depression Receiving Nebulized Glycopyrrolate in the GOLDEN 3 and 4 Studies. Int J Chron Obstruct Pulmon Dis. 2021; 16:865-875.
Score: 0.175
-
Management of asthma COPD overlap. Ann Allergy Asthma Immunol. 2019 10; 123(4):335-344.
Score: 0.156
-
Controversies in Allergy: Should Severe Asthma with Eosinophilic Phenotype Always Be Treated with Anti-IL-5 Therapies. J Allergy Clin Immunol Pract. 2019 May - Jun; 7(5):1430-1436.
Score: 0.153
-
Long-term safety and efficacy of formoterol fumarate inhalation solution in patients with moderate-to-severe COPD. Int J Chron Obstruct Pulmon Dis. 2019; 14:117-127.
Score: 0.150
-
Long-term health-related quality-of-life and symptom response profiles with arformoterol in COPD: results from a 52-week trial. Int J Chron Obstruct Pulmon Dis. 2018; 13:499-508.
Score: 0.141
-
Long-term safety and efficacy of glycopyrrolate/formoterol metered dose inhaler using novel Co-Suspension? Delivery Technology in patients with chronic obstructive pulmonary disease. Respir Med. 2017 05; 126:105-115.
Score: 0.132
-
The Responsiveness of the Anxiety Inventory for Respiratory Disease Scale Following Pulmonary Rehabilitation. Chest. 2016 07; 150(1):188-95.
Score: 0.123
-
Lebrikizumab in moderate-to-severe asthma: pooled data from two randomised placebo-controlled studies. Thorax. 2015 Aug; 70(8):748-56.
Score: 0.117
-
Pooled subpopulation analyses of the effects of roflumilast on exacerbations and lung function in COPD. Respir Med. 2014 Feb; 108(2):366-75.
Score: 0.104
-
The efficacy and safety of the novel long-acting ?2 agonist vilanterol in patients with COPD: a randomized placebo-controlled trial. Chest. 2012 Jul; 142(1):119-127.
Score: 0.096
-
The effects of cigarette smoke on airway inflammation in asthma and COPD: therapeutic implications. Respir Med. 2012 Mar; 106(3):319-28.
Score: 0.092
-
Benefits of adding fluticasone propionate/salmeterol to tiotropium in moderate to severe COPD. Respir Med. 2012 Jan; 106(1):91-101.
Score: 0.091
-
Bronchodilator reversibility in COPD. Chest. 2011 Oct; 140(4):1055-1063.
Score: 0.091
-
A unified front against COPD: clinical practice guidelines from the American College of Physicians, the American College of Chest Physicians, the American Thoracic Society, and the European Respiratory Society. Chest. 2011 Sep; 140(3):565-566.
Score: 0.090
-
Acute bronchodilator responsiveness and health outcomes in COPD patients in the UPLIFT trial. Respir Res. 2011 Jan 11; 12:6.
Score: 0.086
-
Efficacy and safety of nebulized formoterol as add-on therapy in COPD patients receiving maintenance tiotropium bromide: Results from a 6-week, randomized, placebo-controlled, clinical trial. Drugs. 2009 Jun 18; 69(9):1205-16.
Score: 0.077
-
Asthma control: a new perspective on the management of asthma. Curr Opin Pulm Med. 2009 Jan; 15(1):1-3.
Score: 0.075
-
Effect of nebulized arformoterol on airway function in COPD: results from two randomized trials. COPD. 2008 Feb; 5(1):25-34.
Score: 0.070
-
The role of intrinsic efficacy in determining response to a beta2-agonist in acute severe asthma. Respir Med. 2007 May; 101(5):1007-14.
Score: 0.064
-
Revisiting asthma control: how should it best be defined? Pulm Pharmacol Ther. 2007; 20(5):483-92.
Score: 0.062
-
Dupilumab for chronic obstructive pulmonary disease with type 2 inflammation: a pooled analysis of two phase 3, randomised, double-blind, placebo-controlled trials. Lancet Respir Med. 2025 Mar; 13(3):234-243.
Score: 0.057
-
Dupilumab reduces exacerbations and improves lung function in patients with chronic obstructive pulmonary disease and emphysema: Phase 3 randomized trial (BOREAS). Respir Med. 2025 Jan; 236:107846.
Score: 0.056
-
Dupilumab for COPD with Blood Eosinophil Evidence of Type 2 Inflammation. N Engl J Med. 2024 06 27; 390(24):2274-2283.
Score: 0.054
-
Early Evidence of Chronic Obstructive Pulmonary Disease Obscured by Race-Specific Prediction Equations. Am J Respir Crit Care Med. 2024 01 01; 209(1):59-69.
Score: 0.053
-
Clinic vs?Home Spirometry for Monitoring Lung Function in Patients With Asthma. Chest. 2023 11; 164(5):1087-1096.
Score: 0.051
-
Use of the Spirometric "Fixed-Ratio" Underdiagnoses COPD in African-Americans in a Longitudinal Cohort Study. J Gen Intern Med. 2023 10; 38(13):2988-2997.
Score: 0.050
-
Clinical Markers Associated With Risk of Suicide or Drug Overdose Among Individuals With?Smoking Exposure: A Longitudinal Follow-up Study of the COPDGene Cohort. Chest. 2023 02; 163(2):292-302.
Score: 0.049
-
Efficacy of dupilumab on clinical outcomes in patients with asthma and perennial allergic rhinitis. Ann Allergy Asthma Immunol. 2020 11; 125(5):565-576.e1.
Score: 0.041
-
Long-term observational study on the impact of GLP-1R agonists on lung function in diabetic patients. Respir Med. 2019 Jul - Aug; 154:86-92.
Score: 0.039
-
Impact of doxofylline compared to theophylline in asthma: A pooled analysis of functional and clinical outcomes from two multicentre, double-blind, randomized studies (DOROTHEO 1 and DOROTHEO 2). Pulm Pharmacol Ther. 2018 Dec; 53:20-26.
Score: 0.037
-
Effect of exposure to low levels of ozone on the response to inhaled allergen in allergic asthmatic patients. Chest. 1998 Sep; 114(3):752-6.
Score: 0.037
-
Obesity modulates diaphragm curvature in subjects with and without COPD. Am J Physiol Regul Integr Comp Physiol. 2017 Nov 01; 313(5):R620-R629.
Score: 0.034
-
Factors associated with emergency department dependence of patients with asthma. Chest. 1997 Feb; 111(2):290-5.
Score: 0.033
-
Acute Exacerbations and Lung Function Loss in Smokers with and without Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med. 2017 02 01; 195(3):324-330.
Score: 0.033
-
Obesity Is Associated With Increased Morbidity in Moderate to Severe COPD. Chest. 2017 Jan; 151(1):68-77.
Score: 0.032
-
Persistent and Newly Developed Chronic Bronchitis Are Associated with Worse Outcomes in Chronic Obstructive Pulmonary Disease. Ann Am Thorac Soc. 2016 07; 13(7):1016-25.
Score: 0.032
-
Assessing biomarkers in a real-world severe asthma study (ARIETTA). Respir Med. 2016 06; 115:7-12.
Score: 0.031
-
Differences between absolute and predicted values of forced expiratory volumes to classify ventilatory impairment in chronic obstructive pulmonary disease. Respir Med. 2016 Feb; 111:30-8.
Score: 0.030
-
Pneumonia risk with inhaled fluticasone furoate and vilanterol compared with vilanterol alone in patients with COPD. Ann Am Thorac Soc. 2015 Jan; 12(1):27-34.
Score: 0.028
-
Racial differences in CT phenotypes in COPD. COPD. 2013 Feb; 10(1):20-7.
Score: 0.025
-
Lebrikizumab treatment in adults with asthma. N Engl J Med. 2011 Sep 22; 365(12):1088-98.
Score: 0.022
-
Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society. Ann Intern Med. 2011 Aug 02; 155(3):179-91.
Score: 0.022
-
It's about time--directing our attention toward modifying the course of COPD. Respir Med. 2008 Jun; 102 Suppl 1:S37-48.
Score: 0.018
-
Arformoterol and salmeterol in the treatment of chronic obstructive pulmonary disease: a one year evaluation of safety and tolerance. Ther Adv Respir Dis. 2008 Apr; 2(2):37-48.
Score: 0.018
-
Nebulized arformoterol in patients with COPD: a 12-week, multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled trial. Clin Ther. 2007 Feb; 29(2):261-78.
Score: 0.016
-
The efficacy and safety of inhaled fluticasone propionate/salmeterol and ipratropium/albuterol for the treatment of chronic obstructive pulmonary disease: an eight-week, multicenter, randomized, double-blind, double-dummy, parallel-group study. Clin Ther. 2005 May; 27(5):531-42.
Score: 0.015
-
The accuracy of a handheld portable spirometer. Chest. 1996 Jan; 109(1):152-7.
Score: 0.008